Otros idiomas Granules India Limited

Acciones

GRANULES

INE101D01020

Farmacéuticos

Mercado cerrado - Bombay S.E. Otros sitios de cotización 11:00:46 06/02/2026			Variación 5 días	Varia. 1 de enero.
564,30 ^INR	-2,60 %		-1,10 %	-5,72 %

23/01	Granules India Limited, Q3 2026 Earnings Call, Jan 23, 2026
23/01	Los beneficios trimestrales de Granules India se disparan gracias a la fuerte demanda en Norteamérica y Europa	RE

Otros idiomas

28/01	Granules India : SERP Join Handsto Strengthen Breast Cancer Screening in Sangareddy
23/01	Granules India quarterly profit jumps on strong demand in North America, Europe
23/01	Granules Dec-quarter Consol Profit 1.50 Billion Rupees
23/01	Diary - India economic, corporate events on January 23
23/01	Granules India : Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.
23/01	Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
22/01	Diary-India economic, corporate events on January 22
08/01	Granules India : Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)
08/01	Granules India Arm Gets US FDA's Tentative Nod for Amphetamine Extended-Release Tablets
08/01	Granules unit receives FDA tentative approval for generic amphetamine with 180-day exclusivity
05/01	Sigachi Industries Appoints Chief People Officer
23/12	Granules India Limited announced that it expects to receive INR 6.656249925 billion in funding
23/12	Granules India Approves the Proposals to Raise an Aggregate INR 17,625.0 Million Through the Preferential Issuance of Convertible Warrants and Equity Shares
23/12	Granules to issue warrants up to 14.63 billion rupees
23/12	Granules says raising of funds through issuance of shares worth up to 3 billion rupees
22/12	Granules India : Pharmaceuticals Inc. Receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT®)
22/12	Granules India Arm Gets US FDA's Tentative Nod for Generic Amphetamine Extended-Release Tablets
22/12	Granules says unit gets US FDA tentative approval for generic amphetamine extended-release orally disintegrating tablets
19/12	Granules says FDA inspection at unit concludes with five observations
12/12	Granules unit receives EIR from FDA
04/12	Granules India's US Arm Gets Zero Observations from US FDA After GMP Inspection
04/12	Granules's packaging facility in US completes FDA inspection with zero observations
01/12	Granules India : Strengthens RD Leadership with Two New Centres of Excellence at IIT Hyderabads Technology Research Park
01/12	Granules India Opens Two R&D Centers in Hyderabad, India
01/12	Granules India Limited Inaugurates Two Advanced Centres of Excellence At the Technology Research Park of IIT Hyderabad

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Artículos de MarketScreener Estrategias MarketScreener Ideas de trading

Otros idiomas Granules India Limited

Acciones

GRANULES

INE101D01020

Farmacéuticos

Otros idiomas

Filtros